glp-1 shortage over Out of Shortage, Into Controversy: The Fight Compounding The GLP-1 Access Gap: Mapping

How much will be the GLP-1 diabetes treatment drugs market growth between 2025 and 2035

It is an aminopropyl carbazole compound and orally bioavailable, can cross the BBB, and is atoxic when the dose is several times higher than the effective dose (177)

Heres why that matters

L.GoldstrohmA.HookB.ThompsonB.WickensM.et al (2009)

Notably, at physiological concentrations, TMAO can enhance the integrity of the bloodbrain barrier through the tight junction regulator annexin A1, limit the reactivity of astrocytes and microglia, and protect the cognitive function of mice from inflammatory challenges

Some have tried physical therapy, anti-inflammatories, and rest without getting the results they want